Bicycle Therapeutics plc

NASDAQ:BCYC

Biotechnology

Healthcare
$3.11 -1.36%

-$0.06 today

Market cap
$217.99M
Beta
1.54
P/E (TTM)
-1.3
EPS (TTM)
-$3.14
52W Low $3.95High $9.18

Volume 0.57M

Average 0.49M

BCYC Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Bicycle Therapeutics plcNASDAQ: BCYC

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation declines year over year

Q1 FY2026 stock-based compensation of $6.93M fell 27.9% year over year, ahead of the -107.0% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at +13.8% a year.

Context

  • Stock-based compensation amounted to 54.4% of revenue in FY2025, down 53.6 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -27.9% holds above the trailing-twelve-month pace of -107.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.93M+124.9% QoQ
Last fiscal yearDec 2025
$39.46M+3.6% YoY
LTMMar 2026
-$2.68M-107.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-27.9%——
1 year+3.6%——
3-year CAGR+13.8%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
39.46M USD
Year-over-year change
+3.6%
4-year CAGR
+34.4%

Stock-Based Compensation vs competitors

How BCYC compares with its peers on the latest reported figures

  • BCYC's LTM Mar 2026 stock-based compensation of $2.68M is the smallest of the 10 companies compared; the peer median is $12.63M.
  • Its year-over-year change of -107.0% is the lowest of 9, against a peer median of -1.1%.
  • Stock-based compensation amounts to 4.2% of revenue for BCYC, versus a peer median of 20.1%.
BCYC Competitors Peer median
Stock-Based Compensation for BCYC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRTAProthena Corporation plcLTM Mar 2026$33.61M -24.5%+6.3%58.0%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$27.96M -33.3%+53.3%—
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$19.48M -28.2%+8.7%22.1%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$13.16M -4.7%-2.3%—
ADCTADC Therapeutics S.A.LTM Mar 2026$12.63M +26.4%-48.5%16.0%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$12.55M +2.5%+2.8%18.0%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$10.93M +20.5%+16.2%—
OMEROmeros CorporationLTM Mar 2026$5.74M +13.3%—58.0%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$5.38M ——4.6%
BCYCBicycle Therapeutics plcLTM Mar 2026$2.68M -107.0%+13.8%4.2%
Peer median (excluding BCYC) $12.63M-1.1%+6.3%20.1%

Competitors are the stored peer set for BCYC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(66.82M)(112.72M)(180.66M)(169.03M)(218.96M)
Depreciation & Amortization1.41M3.69M6.55M7.17M6.42M
Deferred Income Tax(1.67M)(4.98M)3.31M(5.23M)(850K)
Stock-Based Compensation12.08M26.78M32.48M38.08M39.46M
Change in Working Capital38.07M672K76.66M(33.46M)(75.75M)
Accounts Receivables4.54M(11.35M)(1.2M)(11.95M)2.89M
Inventory(4.79M)0000
Accounts Payables1.2M2.56M8M3.1M(6.87M)
Other Working Capital37.12M9.46M69.86M(24.61M)(71.77M)
Other Non-Cash Items2.14M442K1.04M(2.26M)0
Operating Cash Flow(14.79M)(86.11M)(60.63M)(164.72M)(249.68M)
Capital Expenditures(2.03M)(18.99M)(2.93M)(1.24M)(2.36M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00005.49K
Investing Cash Flow(2.03M)(18.99M)(2.93M)(1.24M)(2.35M)
Debt Repayment15M00(31.91M)0
Common Stock Issued298.54M5.7M249.35M544.13M37.09K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7.18M989K682K7.53M(168.09K)
Financing Cash Flow320.73M6.69M250.03M519.75M(131K)
Effect of Forex Changes(1.21M)(1.12M)1.35M(694K)804K
Net Change in Cash302.69M(99.53M)187.82M353.1M(251.35M)
Free Cash Flow(16.82M)(105.1M)(63.56M)(165.96M)(252.61M)

Bicycle Therapeutics plc

NASDAQ:BCYC

Intrinsic Alpha fair value

Locked

Current Price

$3.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.